These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29706950)

  • 1. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
    Mai Y; Nishie W; Sato K; Hotta M; Izumi K; Ito K; Hosokawa K; Shimizu H
    Front Immunol; 2018; 9():542. PubMed ID: 29706950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
    Nishie W
    Immunol Med; 2019 Mar; 42(1):22-28. PubMed ID: 31169082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.
    Sun L; Wang C; Wu C; Zhou Y; Wang C
    Ann Pharmacother; 2022 Feb; 56(2):205-212. PubMed ID: 34105395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
    Hibi A; Kasahara Y; Ishihara Y; Hata K; Hosokawa N; Nakagawa T
    CEN Case Rep; 2020 Aug; 9(3):189-194. PubMed ID: 31993957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl-peptidase IV inhibitors (DPP4i)-associated bullous pemphigoid: Estimating the clinical profile and exploring intraclass differences.
    Kridin K
    Dermatol Ther; 2020 Jul; 33(4):e13790. PubMed ID: 32506731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.
    Reolid A; Muñoz-Aceituno E; Rodríguez-Jiménez P; González-Rojano E; Llamas-Velasco M; Fraga J; Daudén E
    Int J Dermatol; 2020 Feb; 59(2):197-206. PubMed ID: 31605541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase 4 inhibitor-associated mucous membrane pemphigoid.
    Suezawa M; Dainichi T; Kaku Y; Izumi M; Kataoka K; Ishii N; Koga H; Izumi K; Nishie W
    J Dermatol; 2021 Oct; 48(10):1584-1587. PubMed ID: 34265108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
    Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
    Am J Clin Dermatol; 2021 Jan; 22(1):117-127. PubMed ID: 33026629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor.
    Sawada K; Sawada T; Kobayashi T; Fujiki A; Matsushita T; Kawara S; Izumi K; Nishie W; Shimizu H; Takehara K; Hamaguchi Y
    Immunol Med; 2021 Mar; 44(1):53-55. PubMed ID: 32634333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Tasanen K; Varpuluoma O; Nishie W
    Front Immunol; 2019; 10():1238. PubMed ID: 31275298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis.
    Maki N; Nishie W; Takazawa M; Kakurai M; Yamada T; Umemoto N; Kawase M; Izumi K; Shimizu H; Demitsu T
    J Dermatol; 2018 May; 45(5):600-602. PubMed ID: 29446164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Iwamoto Y; Anno T; Koyama K; Kawasaki F; Kaku K; Tomoda K; Sugiyama S; Aoyama Y; Kaneto H
    Front Immunol; 2022; 13():843480. PubMed ID: 35309321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
    García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
    Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
    Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
    J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: A comparative study of 100 patients with bullous pemphigoid and diabetes mellitus.
    Chanprapaph K; Pratumchart N; Limtong P; Rutnin S; Sukasem C; Kungvalpivat P; Triamchaisri S; Suchonwanit P
    J Dermatol; 2021 Apr; 48(4):486-496. PubMed ID: 33543537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining dipeptidyl peptidase-4 inhibitors-related bullous pemphigoid: A single-centre retrospective study.
    Nieto-Benito LM; Bergón-Sendín M; Pulido-Pérez A; Rosell-Díaz ÁM; Parra-Blanco V; Suárez-Fernández R
    Exp Dermatol; 2021 Sep; 30(9):1345-1351. PubMed ID: 34028898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl Peptidase 4 Inhibitor‒Associated Bullous Pemphigoid Is Characterized by an Altered Expression of Cytokines in the Skin.
    Tuusa J; Kokkonen N; Mattila A; Huilaja L; Varpuluoma O; Rannikko S; Glumoff V; Miettunen J; Tasanen K
    J Invest Dermatol; 2023 Jan; 143(1):78-86.e12. PubMed ID: 35921900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis.
    Hung CT; Chang YL; Wang WM
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases.
    Yoshiji S; Murakami T; Harashima SI; Ko R; Kashima R; Yabe D; Ogura M; Doi K; Inagaki N
    J Diabetes Investig; 2018 Mar; 9(2):445-447. PubMed ID: 28520234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.